This is a summary of the European public assessment report (EPAR) for Mirvaso. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mirvaso.
For practical information about using Mirvaso, patients should read the package leaflet or contact their doctor or pharmacist.
Mirvaso : EPAR - Summary for the public (PDF/82.2 KB)
First published: 14/03/2014
Last updated: 14/03/2014
Mirvaso : EPAR - Risk-management-plan summary (PDF/83.75 KB)
First published: 13/05/2014
Last updated: 13/05/2014
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
La Défense 4
20 avenue André Prothin
92927 La Défense Cedex
25/04/2019 Mirvaso - EMEA/H/C/002642 - IAIN/0023
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Other dermatological preparations
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.